These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 16235978

  • 1. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Mar 08; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May 08; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 5. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
    Keating GM, Plosker GL.
    Drugs; 2004 May 08; 64(23):2689-707. PubMed ID: 15537370
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep 08; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P.
    Cardiovasc Drugs Ther; 2006 Jun 08; 20(3):193-204. PubMed ID: 16775667
    [Abstract] [Full Text] [Related]

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Jun 08; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 08; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of eplerenone in patients with chronic heart failure.
    Ademi Z, Pasupathi K, Krum H, Liew D.
    Am J Cardiovasc Drugs; 2014 Jun 08; 14(3):209-16. PubMed ID: 24610254
    [Abstract] [Full Text] [Related]

  • 11. Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada.
    Thanh NX, Ezekowitz JA, Tran DT, Kaul P.
    Am J Cardiovasc Drugs; 2016 Oct 08; 16(5):365-76. PubMed ID: 27300508
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure.
    McKenna C, Walker S, Lorgelly P, Fenwick E, Burch J, Suekarran S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Palmer S.
    Value Health; 2012 May 08; 15(3):420-8. PubMed ID: 22583451
    [Abstract] [Full Text] [Related]

  • 13. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
    Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA.
    Circulation; 2009 Jan 27; 119(3):398-407. PubMed ID: 19139382
    [Abstract] [Full Text] [Related]

  • 14. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 15. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 16. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J.
    Cardiovasc Drugs Ther; 2001 Jan 14; 15(1):79-87. PubMed ID: 11504167
    [No Abstract] [Full Text] [Related]

  • 17. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 14; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 18. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 14; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 19. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F.
    Circulation; 2012 Jan 17; 125(2):271-9. PubMed ID: 22128223
    [Abstract] [Full Text] [Related]

  • 20. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 17; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.